RVMD Articles

Revolution Medicines Scores First FDA Approval for RAS-Targeted Pancreatic Cancer Drug

The FDA approved Revolution Medicines' RASONQUE (daraxonrasib) for metastatic pancreatic cancer, a first-in-class RAS inhibitor that cut death risk by 60% in a Phase 3 trial. Reddit discussion picked up on the milestone.